AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-19 (cancelled)

Claim 20. (previously presented) A process for making (R)-5-(2-aminopropyl) -2-methoxybenzene sulphonamide comprising the following steps: a) protection of the amino group of D-alanine, b) reaction of the N-protected D-alanine with methoxybenzene to make 4'-methoxy-2-amino protected propiophenone, c) reduction of the oxo-group of the 4'-methoxy-2-amino protected propiophenone to make amino-protected 1-(4-methoxyphenyl)propane-2-amine, d) chlorosulphonation of the amino-protected 1-(4-methoxyphenyl)propane-2-amine and ammonolysis of the chlorosulphonyl group, and e) deprotecton of the amino group.

Claim 21. (previously presented) The process according to claim 20 wherein said protection in step (a) is carried out with ethyl trifluoroacetate.

Claim 22. (previously presented) The process according to claim 20 wherein a Lewis acid is added in step (b).

Claim 23. (currently amended) The process according to claim 22 wherein said Lewis acid ~~comprises~~ is selected from the group consisting of bismuth, titanium, iron (III) or aluminum salt.

Claim 24. (currently amended) The process according to claim 22 wherein said Lewis acid ~~comprises~~ is aluminum chloride.

Claim 25. (previously presented) The process according to claim 20 wherein step (c) is carried out with triethylsilane as a reducing agent.

Claim 26. (previously presented) The process according to claim 20 wherein step (d) is carried out with chlorosulphonic acid as a chlorosulphonation agent.

Claim 27. (previously presented) The process according to claim 20 wherein the reagent for ammonolysis of the chlorosulphonyl group comprises an aqueous solution of ammonia.

Claim 28. (previously presented) The process according to claim 20 wherein deprotection in step (e) is carried out with potassium carbonate.

Claim 29. (previously presented) A process for making tamsulosin or tamsulosin hydrochloride comprising: a) protection of the amino group of D-alanine, b) reaction of the N-protected D-alanine with methoxybenzene to make 4'-methoxy-2-amino protected propiophenone, c) reduction of the oxo-group of the 4'-methoxy-2-amino protected propiophenone to make amino- protected 1-(4-methoxyphenyl)propane-2-amine, d) chlorosulphonation of the amino-protected 1-(4-methoxyphenyl)propane-2-amine and subsequent ammonolysis of the chlorosulphonyl group, e) deprotection of the amino group, and f) o-ethoxy phenoxyethylation of the amino group to make tamsulosin.

Claim 30. (previously presented) The process according to claim 29 wherein said protection in step (a) is carried out with ethyl trifluoroacetate.

Claim 31. (previously presented) The process according to claim 29 wherein a Lewis acid is added in step (b).

Claim 32. (currently amended) The process according to claim 31 wherein said Lewis acid ~~comprises~~ is selected from the group consisting of bismuth, titanium, iron (III) or aluminium salt.

Claim 33. (currently amended) The process according to claim 31 wherein said Lewis acid ~~comprises~~ is iron (III) chloride.

Claim 34. (previously presented) The process according to claim 29 wherein step (c) is carried out with triethylsilane as a reducing agent.

Claim 35. (previously presented) The process according to claim 29 wherein step (d) is carried out with chlorosulphonic acid as a chlorosulphonation agent.

Claim 36. (previously presented) The process according to claim 29 wherein the reagent for ammonolysis of the chlorosulphonyl group comprises an aqueous solution of ammonia.

Claim 37. (previously presented) The process according to claim 29 wherein the deprotection in step (e) is carried out with potassium carbonate.

Claim 38. (currently amended) An intermediate derivative for use in the production of tamsulosin or pharmaceutically effective salts thereof which comprises
(R)-1-(4-methoxy-3-sulphamoylphenyl)-2-trifluoroacetylaminopropane.

Claim 39. (currently amended) An intermediate derivative for use in the production of tamsulosin or pharmaceutically effective salts thereof which comprises
(R)-1-(4-methoxy-3-sulphamoylphenyl)-2-trifluoroacetylamino-1-propanone.

Claim 40. (previously presented) The process according to claim 29 further comprising the step of treating the tamsulosin with ethanolic HCl to make tamsulosin hydrochloride.